stockrow
Friday 6 November 2026
Export SKIN’s income statement to Excel — free account
SkinHealth Systems Inc.
SKIN Consumer Defensive Household & Personal Products
SkinHealth Systems Inc.’s revenue for fiscal 2025 (year ended December 2025) was $300.8 million, down 10.0% from fiscal 2024.
- Revenue
- −2.10%
- EPS
- −112.5%
- Free cash flow
- +19.1%
- Total debt
- −33.1%
Quarter to September 2026, against a year earlier
15.79
5.44
+52.56%
Follow SKIN
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.28 | 0.31 | 0.38 | 0.58 | |
P/FCF ratio |
4.47 | 5.39 | 4.89 | 5.43 | |
P/Operating CF |
7.25 | 33.60 | (20.48) | 11.56 | |
P/B ratio |
1.46 | 1.62 | 2.06 | 2.88 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.09 | 0.79 | 0.86 | 1.02 | |
EV/EBITDA |
13.10 | 9.51 | 14.25 | 37.57 | |
EV/Operating CF |
13.37 | 10.42 | 8.76 | 8.20 | |
EV/FCF |
17.25 | 13.75 | 10.90 | 9.51 | |
Quick Ratio |
1.90 | 1.34 | 1.45 | 1.37 | |
Current Ratio |
2.89 | 1.76 | 1.79 | 1.66 | |
Net Debt/EBITDA |
0.00 | 14.15 | 30.77 | 20.18 | |
Debt/Assets |
62.45% | 70.95% | 72.74% | 72.91% | |
Debt/Equity |
4.36 | 6.21 | 6.23 | 5.97 | |
Asset Turnover |
0.65 | 0.58 | 0.52 | 0.51 | |
Operating CF/Net income |
(12.68) | (1.00) | 0.84 | (1.88) | |
Capex/Depreciation |
0.00 | (0.19) | (0.26) | (0.22) | |
Interest Coverage |
0.79 | 0.57 | (0.28) | 0.03 | |
Research and Development Expense of Revenue |
2.40% | 1.95% | 1.70% | 2.04% | |
Selling, General and Administrative Expense of Revenue |
58.56% | 61.51% | 69.54% | 62.15% | |
Intangible Assets out of Total Assets |
0.40 | 0.32 | 0.34 | 0.32 | |
Share Based Compensation of Revenue |
2.08% | 4.01% | 3.20% | 4.35% | |
Graham Net Nets |
(1.61) | (1.51) | (1.23) | (0.74) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(34.92%) | (31.77%) | (4.49%) | (5.04%) | |
Free Cash Flow Yield |
22.39% | 18.54% | 20.46% | 18.40% | |
Revenue per Share |
0.00 | 11.13 | 10.16 | 13.04 | |
Operating CF per Share |
0.00 | 0.41 | (0.87) | 2.40 | |
Capex per Share |
0.00 | (0.19) | (0.26) | (0.22) | |
Free Cash Flow per Share |
0.00 | 0.23 | (1.13) | 2.19 | |
Cash per Share |
0.00 | 31.80 | 31.98 | 36.82 | |
Shareholders Equity per Share |
0.00 | 8.58 | 8.65 | 9.66 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 8.58 | 8.65 | 9.66 | |
Free Cash Flow |
10.20 | 1.47 | (7.20) | 13.81 | |
Working Capital |
131.75 | 127.04 | 122.49 | 123.24 | |
Capital Expenditures |
(1.06) | (1.20) | (1.65) | (1.38) | |
Net Current Asset Value |
(131.72) | (135.76) | (140.30) | (129.23) | |
EV/EBIT |
45.62 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.02 | 0.03 | 0.02 | |
Price to Operating Income |
11.81 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
22.85 | 23.38 | 21.89 | 25.95 | |
Average Payables |
16.19 | 19.51 | 19.51 | 18.79 | |
Average Inventory |
51.20 | 53.01 | 56.66 | 58.56 | |
Average Assets |
446.35 | 497.07 | 573.53 | 592.74 | |
Average Common Equity |
60.71 | 64.79 | 50.65 | 56.43 |
Columns are period end dates · fundamentals updated 5 Nov 2026